Skip to content

Author

Esmeraldito Ferreira

1 paper indexed here

We haven’t gathered this author’s papers yet. Follow them and we’ll fetch their work.

Not the right person? Other researchers publish under this name.

Open access Nov 2026

Effectiveness and Safety of Vunakizumab Over 12 Weeks in Chinese Patients With Plaque Psoriasis: A Prospective, Real-World Cohort Study.

Vunakizumab is a humanized anti-IL-17A monoclonal antibody approved in China for moderate-to-severe plaque psoriasis. Real-world data on its effectiveness and predictors of response remain scarce. This prospective, single-center, observational study enrolled 34 adults receiving vunakizumab (240 mg subcutaneously at wee...

Tong Wu, Esmeraldito Ferreira, Guang-Yu Peng et al. · 0 citations

We use cookies to run the site and, with your consent, for analytics and to show ads. See our Cookie Policy.